MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours

Combining drugs, which target different signalling pathways, often decreases adverse side effects while increasing the efficacy of treatment. The objective of our study was to determine if the combination of our novel atypical retinoic acid metabolism-blocking agent (RAMBA) VN/66-1 and a promising h...

Descripción completa

Detalles Bibliográficos
Autores principales: Khandelwal, A, Gediya, L K, Njar, V C O
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359640/
https://www.ncbi.nlm.nih.gov/pubmed/18349838
http://dx.doi.org/10.1038/sj.bjc.6604295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359640/
https://www.ncbi.nlm.nih.gov/pubmed/18349838
http://dx.doi.org/10.1038/sj.bjc.6604295

Ejemplares similares